Abstract
Introduction
multidrug regimen directed against drug-resistant organisms [3] . Nevertheless, Kett et al.
1
[10] reported that compliance with ATS/IDSA guidelines for dual gram-negative 2 coverage in patients, who are at risk from multidrug-resistant pathogens, was associated 3 with increased mortality. This can be explained by antibiotic-specific toxic effects such 4 as acute deterioration of renal function or neurotoxic effects. Brito et al. [11] developed 5 an algorithm for empiric therapy of HCAP that suggests that not all such patients 6 require a broad-spectrum multidrug regimen to achieve appropriate and effective antibiotic therapy in the past 6 months, poor functional status, and immune suppression.
10
For HCAP treatment, piperacillin/tazobactam hydrate (PIPC/TAZ) and 11 carbapenems such as meropenem hydrate (MEPM) are recommended. However, limited 12 data is available for comparing the effects of these two antibiotics against HCAP. In this 13 study, the efficacy and safety of initial empiric therapy with PIPC/TAZ was compared to 14 that with MEPM in patients with HCAP in Japan.
15
We enrolled patients with HCAP from Nagasaki University Hospital and 14 1 affiliated facilities in Nagasaki Prefecture from October 1, 2009 , to May 31, 2010 . The 2 study was conducted with prior approval from the ethics committee of each of the 3 participating medical facilities and was registered on a clinical trial registry (UMIN ID 4 No.: UMIN000002269). The study protocol was explained thoroughly to the patients or 5 their legal representatives before the start of treatment, and written informed consent 6 was obtained from each patient.
7
Patients with HCAP and a pneumonia severity index score [12] in risk class III 8 or IV were required to fulfill all four of the following criteria: (1) appearance of new 9 infiltrates on chest radiography or computed tomography; (2) either (a) resided in a 10 nursing home, long-term care facility or extended-care ward (for more than 48 h), ( with pneumonia severity index score in risk class V; and (10) those who were judged as 9 otherwise ineligible by the attending physicians.
10
For the safety analysis, all randomized patients who received at least one dose 11 of the study medication were included. Among full analysis set (FAS) which included 12 all subjects who received at least one dose of the study medication during this study and with no protocol violations (per-protocol set; PPS) were included for efficacy analysis.
were randomly allocated to receive either PIPC/TAZ (4.5 g) every 8 h or MEPM (0.5 g) type of adverse event, and severity were recorded and evaluated for such events.
16

Statistical analysis
17
The data were analyzed using SAS version 9.2 (SAS Institute Inc., Cary, NC).
18
P-values less than 0.05 were considered statistically significant. We designed a trial to compare two broad-spectrum single-agent regimens with 12 gram-negative and anaerobic coverage; we compared the efficacy and safety of 13 PIPC/TAZ with those of MEPM in patients with HCAP in Japan. The dosages of the 14 drugs under study were 13.5 g/day (PIPC/TAZ) and 1.5 g/day (MEPM). MEPM was not 15 approved for use at dosages of more than 1.5 g/day during the study period in Japan.
16
Although not statistically different, the PIPC/TAZ group had a slightly higher efficacy HCAP in Japan. A further confirmatory study with a larger cohort as determined by a 10 power analysis is recommended.
11
In conclusion, although not statistically different, the PIPC/TAZ group had a 12 slightly higher efficacy rate than the MEPM group. Both treatment regimens are 13 considered to be safe as initial empiric therapy for HCAP in Japanese patients. To 14 investigate the differences in efficacy profiles of these two regimens, a further 15 confirmatory study with a larger number of patients is necessary. 
